977 results about "Quinoxaline" patented technology

The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α₂ adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.

Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

It is an object to provide a novel bipolar organic compound. In particular, it is an object to provide a bipolar organic compound excellent in thermal stability. Further, it is another object to provide a bipolar organic compound which is electrochemically stable. A quinoxaline derivative represented by a general formula (1) is provided. Further, since the quinoxaline derivative represented by the general formula (1) is bipolar, the use of the quinoxaline derivative of the present invention allows fabrication of a light-emitting element and a light-emitting device with a low driving voltage and low power consumption. Furthermore, a light-emitting element with high luminous efficiency can be obtained.

Quinoxaline compounds, compositions, methods of making them, and methods of using them in leukocyte recruitment inhibition, in modulating an H₄ receptor, and in treating conditions such as inflammation, H₄ receptor-mediated conditions, and related conditions.

An organometallic compound comprising a quinoxaline structure, and having a structure represented by the following general formula (2),

wherein M represents a monovalent to trivalent metal, L represents a ligand, Ar₁ and Ar₂ represent an aryl group in which a part of hydrogens may be substituted, and the same or different, m represents an integer of 1 to 3, n represents an integer of 0 to 2, and m-n is an integer of 1 to 3.

The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of IkappaB kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

A quinoxaline-based, new bipolar organic compound is provided, and a light emitting element using the quinoxaline-based compound is demonstrated. The quinoxaline derivative of the invention has a structure in which carbon at one or both of the 2-position and the 3-position of the quinoxaline unit are bonded, via an arylene group, with an amine unit which has a substituted or unsubstituted five-membered ring or a substituted or unsubstituted condensed ring containing a five-membered ring structure. The quinoxaline-based compound was proven to possess bipolar characteristics in view of carrier transportation, which allows the fabrication of a light emitting element and an electronic appliance with a low driving voltage and low power consumption.

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

An optically active 2,3-bis(dialkylphosphino)pyrazine derivative represented by formula (1) is disclosed. The pyrazine derivative is preferably a quinoxaline derivative represented by formula (2). In formula (1) and (2), R¹ is preferably a t-butyl or adamantyl group, and R² is preferably a methyl group.

• • wherein R¹ is a substituted or unsubstituted, straight chain or branched alkyl group having 2 to 10 carbon atoms; R² is a substituted or unsubstituted, straight chain or branched alkyl group having fewer carbon atoms than R¹; and R³ and R⁴, which may be the same or different, are each a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R³ and R⁴ are taken together to form a saturated or unsaturated ring.
  • wherein R¹ and R² are as defined above; and R⁵ is a monovalent substituent.

Provided is a novel heterocyclic compound which has excellent heat resistance and can be used as a host material for a light-emitting substance (a substance emitting fluorescence or a substance emitting phosphorescence). A light-emitting element includes a heterocyclic compound which includes one dibenzo[f,h]quinoxaline ring, one ring having a hole-transport skeleton, and two to eight benzene rings. Note that in the above structure, the molecular weight of the heterocyclic compound is greater than or equal to 564 and less than or equal to 1000.

The invention discloses a pyrazolo N-substituted dehydronorcantharidin imide derivative as well as a synthesis method, an activity test method and application thereof, belonging to the field of cantharidin derivatives. The pyrazolo N-substituted dehydronorcantharidin imide derivative has a structural general formula shown as a formula 1: in the formula 1, R1 is H, C1, F, CH3, OCH3, OH or NO2; and R2 is 2-phenyl-2H-1,2,3-triazole-4-substituent or quinoxaline-2-substituent. The novel N-substituted dehydronorcantharidin imide derivative introduces five-membered heterocyclic pyrazole rings into norcantharidin substituted arylamine and has favorable anti-tumor activity.

The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Clear, high load water miscible emulsions of quinoxalinyl ester herbicides, particularly quizalofop-p-ethyl, as a single phase, translocatable composition which is free of xylene and alkylphenol ethoxylate surfactants and concentrate matrix for the active quinoxalinyl ester component at between about 9 and about 25 wt. % active concentration.

The present invention is to provide quinoxaline derivatives, which has excellent electron transportation and hole blocking properties, and which can be formed into a film without being crystallized. According to the invention, quinoxaline derivatives represented by the general [formula 1] is synthesized.

(wherein X and Y represent a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, and R1 to R6 represent individually hydrogen, an alkyl group, an alkoxyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group. Further, an organic semiconductor device including an electroluminescent device containing the foregoing quinoxaline derivatives is formed.)

To provide a new bipolar organic compound. In particular, to provide a bipolar organic compound having excellent heat resistance and to provide a bipolar organic compound which is electrochemically stable. Further, to provide a light emitting element and a light emitting device of which a driving voltage and power consumption are reduced by using a new bipolar organic compound. Further, to provide a light emitting element and a light emitting device which have excellent heat resistance by using a new bipolar organic compound. Further, to provide a light emitting element and a light emitting device which have a long life by using a new bipolar organic compound.

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.